GlassScriptPhysician profile
Allan M Burke
NPI 1255314803
$4,214.42
in general payments reported to CMS, 2019-2025
34 companies · $2,165 in 2025
The $2,165 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $105 · 2021: $19.18 · 2022: $268 · 2023: $422 · 2024: $1,058 · 2025: $2,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,610 · Education: $35.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,610.23 |
| Education | $35.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $594.34 | 2024-2025 | |
| Abbvie INC. | $501.48 | 2022-2025 | Qulipta, Botox, Ubrelvy |
| Csl Behring | $397.27 | 2022-2025 | Hizentra, Privigen |
| Teva Pharmaceuticals USA, INC. | $316.12 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Lilly USA, LLC | $251.16 | 2023-2025 | Kisunla, Emgality, Amyvid |
| Biogen, INC. | $212.85 | 2020-2025 | Tysabri, Tysabri, Vumerity |
| Eisai INC. | $190.24 | 2024-2025 | |
| Genentech USA, INC. | $187.77 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Argenx US, INC. | $163.11 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Ipsen Biopharmaceuticals, INC | $141.85 | 2024-2025 | Dysport |
| Acadia Pharmaceuticals INC | $118.65 | 2025 | Nuplazid |
| Celgene Corporation | $105.17 | 2024-2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $105.07 | 2019-2024 | Qelbree |
| Azurity Pharmaceuticals, INC. | $95.55 | 2024-2025 | Horizant |
| Pfizer INC. | $89.98 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $76.04 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $68.94 | 2019-2020 | |
| Lundbeck LLC | $64.80 | 2024 | Vyepti |
| Mdd US Operations, LLC | $60.95 | 2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $59.46 | 2025 | Rexulti |
| Kyowa Kirin, INC. | $53.93 | 2024 | Nourianz |
| Takeda Pharmaceuticals U.S.A., INC. | $47.53 | 2023 | |
| Janssen Biotech, INC. | $47.49 | 2025 | |
| Sunovion Pharmaceuticals INC. | $42.83 | 2019 | |
| Tg Therapeutics, INC. | $35.09 | 2025 | |
| Genzyme Corporation | $32.52 | 2025 | |
| Abbott Laboratories | $31.21 | 2025 | Proclaim |
| Livanova USA, INC. | $23.22 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Catalyst Pharmaceuticals, INC. | $18.27 | 2025 | |
| Amgen INC. | $17.92 | 2023 | Aimovig |
| Ucb, INC. | $17.64 | 2025 | Zilbrysq |
| Axsome Therapeutics, INC. | $16.63 | 2025 | Symbravo |
| Alexion Pharmaceuticals, INC. | $15.00 | 2025 | Ultomiris |
| Avion Pharmaceuticals | $14.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.